Long ‐term lamivudine therapy in chronic hepatitis B
ConclusionsLong‐term viral suppression with nucleoside analogues leads to HBsAg loss in a substantial proportion of patients, particularly if HBeAg‐negative. Serious outcomes during the first 10–20 years of treatment occur largely among patients with pre‐existing cirrhosis who do not clear HBsAg with therapy.
Source: Alimentary Pharmacology and Therapeutics - Category: Drugs & Pharmacology Authors: S. Lingala, D. T. ‐Y. Lau, C. Koh, S. Auh, M. G. Ghany, J. H. Hoofnagle Tags: Original Article Source Type: research
More News: Cancer | Cancer & Oncology | Cirrhosis | Drugs & Pharmacology | Hepatitis | Hepatitis B | Liver | Liver Disease | Liver Transplant | Oral Cancer | Transplants | Urology & Nephrology